ChromoTek wins INDUSTRY PRIZE 2013 for its pioneering Chromobody® technology for the real time analysis of cellular molecules in live cells
With its Chromobody® technology, the Martinsried based biotech company intends to speed up drug development by providing more intelligent cellular bioassays
(PresseBox) - How drugs influence cellular proteins is a vital question in drug development both to unravel their mode of action and to detect possible side effects early on. So far, such analyses have required time-consuming series of experiments, in which cell samples had to be fixed at different time points after the addition of drug candidates. Since the test cells don't survive this procedure, one needs many measuring points for a time course, which yield still images of the target proteins in dead cells only.
A much simpler and more elegant solution is available from ChromoTek. The company based in Martinsried, Germany's premier biotech cluster, has developed the "Chromobody®" technology, a novel fluorescent method allowing the direct spatial and temporal monitoring of endogeneous cellular target proteins in live cells in real time, which is nothing short of a molecular movie. In reward for this innovation, ChromoTek has been selected as the overall winner of the prestigious INDUSTRY PRIZE 2013 at this year's HANNOVER fair.
Since 2006, the INDUSTRY PRIZE is awarded by Huber Publishing for New Media and the Small Business Initiative in 14 different categories. An expert jury rates the technological, economical, ecological or social value of the products and the companies. More than 1200 participants have contested for the prize this year. "We are very happy with the decision of the jury to choose ChromoTek as the overall winner of the INDUSTRY PRIZE 2013" says managing director Marion Jung. "This underscores the importance of our technology offering. We do hope that the publicity associated with this award will contribute to our continued market success".
ChromoTek products set new benchmarks in cellular research. Established in 2008 as a spin-off from Munich's Ludwig Maximilian University, ChromoTek is located in Martinsried, Germany's leading biotech cluster.
ChromoTek develops and markets immunological and bioimaging reagents and cellular assays for biomedical research and drug discovery and offers screening services. Main products are the GFP-Trap® for the rapid pull-down of GFP fusion proteins, the GFP- and RFP-Booster for intensifying the fluorescence signal of GFP or RFP fusion proteins, Chromobody® based live cell assays for screening and validation as well as a selection of conventional monoclonal antibodies. About 3,000 customers from all over the world trust in ChromoTek products.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
ChromoTek products set new benchmarks in cellular research. Established in 2008 as a spin-off from Munich's Ludwig Maximilian University, ChromoTek is located in Martinsried, Germany's leading biotech cluster.
ChromoTek develops and markets immunological and bioimaging reagents and cellular assays for biomedical research and drug discovery and offers screening services. Main products are the GFP-Trap® for the rapid pull-down of GFP fusion proteins, the GFP- and RFP-Booster for intensifying the fluorescence signal of GFP or RFP fusion proteins, Chromobody® based live cell assays for screening and validation as well as a selection of conventional monoclonal antibodies. About 3,000 customers from all over the world trust in ChromoTek products.
Datum: 18.04.2013 - 05:00 Uhr
Sprache: Deutsch
News-ID 1217632
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Planegg-Martinsried
Phone:
Kategorie:
Handcrafts
Anmerkungen:
Diese Pressemitteilung wurde bisher 287 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ChromoTek wins INDUSTRY PRIZE 2013 for its pioneering Chromobody® technology for the real time analysis of cellular molecules in live cells
"
steht unter der journalistisch-redaktionellen Verantwortung von
ChromoTek GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
